RadioMedix Debuts Proprietary bench top 212Pb Generator to Support Targeted Alpha Therapy Development

June 12, 2025

Sanofi, RadioMedix, and Orano Med Announce Licensing Agreement for Next-Generation Radioligand Medicine Targeting Rare Cancers

September 12, 2024

RadioMedix and Orano Med Complete Patient Enrolment in Phase II Trial of Targeted Alpha-Emitter AlphaMedix in Neuroendocrine Cancers

May 16, 2024

RadioMedix and Orano Med receive FDA Breakthrough Therapy Designation for AlphaMedixTM in gastroenteropancreatic neuroendocrine tumors

February 12, 2024

RadioMedix Inc. Announces the Acquisition of its 225Ac-PSMA I&T program, a Targeted Alpha Therapy (TAT) for Metastatic Castration Resistant Prostate Cancer, by Fusion Pharmaceuticals Inc.

February 15, 2023

RadioMedix announces a $40 million Series A financing for the advancement of novel Targeted Alpha Therapy platform and diagnostic companion radiopharmaceuticals to address unmet needs in oncology. Michael Lee-Chin appointed to the board of the company.

October 6, 2022

RadioMedix and Vect-Horus announce first dosing of Glioblastoma Multiforme and Pancreatic ductal adenocarcinoma patients with 68Ga-RMX-VH

November 17, 2021

In The News

Houston’s life sciences ecosystem gains momentum with support from RadioMedix and others

BioSpace highlights Houston’s expanding biotech scene, featuring insights from RadioMedix CEO Ebrahim Delpassand on the city’s strengths in oncology and radiopharmaceutical innovation.

Copyright © 2025 RadioMedix, Inc. is a clinical stage biotechnology company, based in Houston, Texas. | Powered by RadioMedix

Quick Link

Contact Info